相关实验视频

Updated: Jan 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

[非小细胞肺癌中不可逆转EGFR-TKI的研究现状和未来方向]

M X Fang¹, W D Wu¹, X X Yu²

¹Department of Cardiothoracic and Vascular Surgery, Guangzhou Red Cross Hospital (Guangzhou Red Cross Hospital of Jinan University), Guangzhou 510220, China.

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

|September 9, 2025

概括

不可逆的表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 通过克服耐药性,为EGFR突变非小细胞肺癌 (NSCLC) 提供了改善的治疗方法. 这些药物在组合疗法和个性化治疗策略中表现有前途.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 对EGFR突变非小细胞肺癌 (NSCLC) 至关重要.
第一代和第二代EGFR-TKI由于获得的耐药性,特别是T790M突变而表现出局限性.
不可逆转的EGFR-TKI代表了克服获得性耐药性的重大进展.

研究的目的:

系统地审查不可逆转EGFR-TKI的作用机制.
总结临床研究进展和不可逆转EGFR-TKI的未来方向.
探索克服药物耐药性的策略,组合治疗和生物标志物引导的个性化治疗.

主要方法:

系统的文献审查.
对不可逆转的EGFR-TKI进行临床前和临床研究的分析.
对抗性机制和治疗策略的评估.

主要成果:

不可逆转的EGFR-TKI利用共价结合机制来增强抗药性突变的抑制.
这些药物已显示出在EGFR突变NSCLC中延长患者生存的潜力.
组合疗法和个性化方法正在成为关键策略.

结论:

不可逆转的EGFR-TKI是克服EGFR突变NSCLC耐药性的有希望的治疗选择.
对组合治疗和生物标志物引导治疗的进一步研究是有必要的.
这些药物具有改善临床实践和患者治疗结果的巨大潜力.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...